Conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus envelope, nucleic acid molecules, expression vectors, neutralizing antibodies and their applications
By displaying the conservative neutralization epitope QT7 of PRRSV-2 encapsular glycoprotein GP5 on the surface of recombinant strains, combining neutralizing antibodies, and using plate agglutination assay detection method, the cell neutralization test was solved in the detection of pig reproductive and respiratory syndrome viruses. The inconsistency and high cost problems with antibodies have achieved rapid, convenient and highly specific detection effects, and are suitable for rapid detection of large-scale pig farms.
Patent Information
- Application Number
- CN202410695247.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-31
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2044-05-31
AI Technical Summary
Existing cell neutralization tests have problems such as inconsistent results, high cost, long time, low sensitivity and unsuitable for early detection when detecting pig reproductive and respiratory syndrome virus (PRRSV-2) neutralizing antibodies, and are subject to different strains of poisoning. and cell type have a greater impact.
The conservative neutralizing epitope QT7 and its nucleic acid molecule of the main glycoprotein GP5 of North American pig reproductive and respiratory syndrome virus capsule were provided. Through recombinant expression vectors and recombinant strains, the plate agglutination test was used to detect Peg pie The system expresses QT7 on the surface of inert vector bacteria and binds to neutralizing antibodies for in vitro detection.
Achieve fast, convenient, low-cost, strong specificity and high sensitivity detection methods, overcome the limitations of cell neutralization tests, and the detection results are highly correlated with cell neutralization tests, and are suitable for large-scale rapid mass of large-scale pig farms. Test, with good repeatability and stability.
Smart Images

Figure CN118496323B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and biomedicine, and specifically relates to a conserved neutralizing epitope QT7 of the major envelope glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus, a nucleic acid molecule, an expression vector and a neutralizing antibody and applications thereof. Background Art
[0002] Porcine reproductive and respiratory syndrome (PRRS), also known as blue ear disease, is an immunosuppressive disease caused by porcine reproductive and respiratory syndrome virus (PRRSV), characterized by reproductive disorders in sows and respiratory symptoms in pigs at all stages. PRRS is an important pig disease that endangers the healthy development of the global pig industry. Therefore, the prevention and control of PRRS is of great economic significance.
[0003] PRRSV is a single-stranded positive-sense RNA virus with an envelope. The genome is about 15kb long and consists of 10 open reading frames. The GP5 glycoprotein encoded by ORF5 is located on the surface of the virus particle and is present in high levels in the virus. It is the main glycoprotein of the envelope and the main target for the body to produce neutralizing antibodies against PRRSV. Since PRRSV was first discovered in the 1980s, PRRSV has undergone rapid evolution. In July 2021, the International Committee on Taxonomy of Viruses (ICTV) divided PRRSV into two different pathogens, namely PRRSV-1 (European type PRRSV) and PRRSV-2 (North American type PRRSV). At present, the main PRRSV-2 is prevalent in my country, and a situation has been formed in which NADC30-like strains are dominant and multiple subtypes (classical type, highly pathogenic type, QYYZ type, NADC30-like type, NADC34-like type) coexist, posing challenges to PRRSV prevention and control.
[0004] The main measure for preventing PRRS in my country is to use the corresponding vaccine. PRRSV neutralizing antibodies in animals are an important indicator for evaluating the effectiveness of PRRSV vaccines and monitoring the immune / infection status of pig herds. At present, the classic cell neutralization test is widely used for in vitro detection of PRRSV neutralizing antibodies in samples (serum), but for in vitro detection of PRRSV neutralizing antibodies, the classic cell neutralization test has the following limitations:
[0005] First, there are many susceptible cell types and strains that can be selected when using cell neutralization tests to detect PRRSV neutralizing antibodies, which leads to inconsistent test results between different units, laboratories and operating technicians, and lacks standard parameters when comparing test results. In terms of susceptible cells, for the most commonly used MARC-145 cell line and PAM (porcine alveolar macrophage) primary cells for PRRSV in vitro culture, there are certain differences in the amino acids of the PRRSV virus receptor CD163 on the surface of monkey-derived MARC-145 susceptible passage cells and pig-derived PAM susceptible primary cells. At the same time, there are certain differences in the cell viability and metabolism of MARC-145 cells with different passage times, and there are batch differences in PAM cells prepared from different batches. These factors may cause different PRRSV neutralizing antibody results for the same sample using different cells; in terms of virus selection, PRRSV has multiple subtypes of strains, and strains of different lineages have different virulence and different adaptability to susceptible cells. Using different strains for cell neutralization tests will also cause differences in results.
[0006] Second, the complex components in the sample (serum) interfere with the results of the cell neutralization test. Serum has very complex components, including proteins, growth factors, ions, etc., and there may be some non-specific antiviral substances, such as IFN-γ, when the body is infected with other pathogens. The high content of protein in serum (up to 66-81 mg / mL) may affect the interaction between viral ligand proteins and host receptor proteins, thereby affecting viral adsorption and other infection processes; non-specific antiviral substances will kill viruses and help susceptible cells resist viral infection, resulting in a high measured PRRSV neutralizing antibody titer. Therefore, when conducting a cell neutralization test, the sample (serum) must be diluted, or the neutralization titer must reach a certain titer to be considered positive, but this artificial regulation cannot truly reflect the positive and negative nature of the PRRSV neutralizing antibodies in the sample.
[0007] Third, the cell neutralization test is time-consuming, labor-intensive, and has low throughput. The cell neutralization test requires the manipulation of live viruses and the cultivation of cells. It requires professional laboratory personnel, professional laboratory instruments, and expensive sera and antibodies, which are time-consuming, labor-intensive, and have low throughput. At the same time, the cell neutralization test is generally used to detect PRRSV neutralizing antibodies in 96-well plates, and the test sample volume is very limited. The high cost and limited test volume limit the use of cell neutralization tests in large-scale pig farms to evaluate the immune effects of vaccines and monitor the immune / infection status of pig herds.
[0008] Fourth, the sensitivity of the cell neutralization test is not high and is not suitable for early detection and monitoring of PRRSV neutralizing antibodies.
[0009] Fifth, in order to improve the sensitivity of the cell neutralization test and reduce the time cost, some people use immunofluorescence (IFA) to observe whether the virus has lost the ability to infect susceptible cells, and then determine the PRRSV neutralizing antibody titer. However, the use of secondary antibodies and fluorescence microscopes makes the detection cost more expensive; and it is generally believed that a 90% reduction in fluorescence in the cell well is considered positive, which is subjective. At the same time, the nonspecific binding of antibodies and nonspecific fluorescence after cell apoptosis make the detected PRRSV neutralizing antibody titer low. The secondary antibody will be left for a long time after use, which will cause fluorescence quenching, making the detected PRRSV neutralizing antibody titer high.
[0010] Based on the limitations of the above-mentioned classic cell neutralization test in detecting PRRSV neutralizing antibodies, there is an urgent need for a detection reagent and method that is fast, convenient, low-cost, highly specific, highly sensitive, not affected by different strains and different cells, and has stable and reproducible results. Summary of the invention
[0011] Purpose of the invention: The technical problem to be solved by the present invention is to provide a conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the PRRSV-2 viral envelope and its neutralizing antibody, which can directly mediate a plate agglutination test and conveniently detect PRRSV-2 neutralizing antibodies in vitro.
[0012] The technical problem that the present invention needs to solve is to provide a nucleic acid molecule encoding the conserved neutralization epitope QT7.
[0013] The technical problem that the present invention needs to solve is to provide an expression cassette, a recombinant expression vector, a recombinant cell or a recombinant strain.
[0014] The technical problem that the present invention also aims to solve is to provide a method for constructing a recombinant expression vector or a recombinant strain.
[0015] The technical problem that the present invention also aims to solve is to provide the use of the neutralizing epitope QT7, the nucleic acid molecule, the peg-PRRSV-QT7 gene fragment, the expression cassette, the recombinant expression vector, the recombinant cell or the recombinant strain in the preparation of a reagent or a kit for detecting PRRSV-2 and its neutralizing antibodies.
[0016] The final technical problem to be solved by the present invention is to provide a detection system or detection kit for North American porcine reproductive and respiratory syndrome virus or its neutralizing antibodies, characterized in that the detection system or detection kit for North American porcine reproductive and respiratory syndrome virus or its antibodies includes the expression cassette, recombinant expression vector, recombinant cell or recombinant strain.
[0017] Technical solution: In order to solve the above technical problems, the present invention provides a conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus (PRRSV-2) envelope, and the amino acid sequence of the conserved neutralizing epitope QT7 is QLIYNLT.
[0018] Wherein, the QT7 is the 40th to 46th amino acid residues from the N-terminus of the PRRSV-2 GP5 protein.
[0019] The present invention also provides a nucleic acid molecule encoding the conserved neutralization epitope QT7, and the nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.1.
[0020] The present invention also provides a peg-PRRSV-QT7 gene fragment, the nucleotide sequence of which is shown in SEQ ID NO.2.
[0021] The present invention also provides a recombinant protein expressing the conserved neutralization epitope QT7, and the amino acid sequence of the recombinant protein is shown in SEQ ID NO.3.
[0022] The present invention also provides an expression cassette, a recombinant expression vector, a recombinant cell or a recombinant strain, which comprises the nucleic acid molecule or the peg-PRRSV-QT7 gene fragment.
[0023] The present invention also provides a method for constructing the recombinant expression vector, comprising the following steps:
[0024] (1) obtaining the gene sequence of the conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus envelope, the nucleotide sequence of which is shown in SEQ ID NO.1;
[0025] (2) Inserting the gene sequence obtained in step (1) into the Peg pili encoding gene sequence to construct a recombinant expression vector.
[0026] Specifically, the present invention also provides an expression vector pBR-peg-PRRSV-QT7, in which a DNA sequence of a conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus (PRRSV-2) envelope is inserted into the coding gene sequence of the Peg fimbriae of Salmonella pullorum, and the coding gene sequence of the Peg fimbriae of Gallinarum typhoid carrying the conserved neutralizing epitope QT7 is cloned into a pBR322 vector for expression, thereby obtaining the pBR-peg-PRRSV-QT7 expression vector.
[0027] The present invention also provides a method for constructing the recombinant strain, comprising the following steps: introducing the recombinant expression vector into the carrier bacteria by means of electrotransformation.
[0028] Specifically, the present invention also provides a S9H-pBR-peg-PRRSV-QT7 recombinant bacterium that displays the conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus (PRRSV-2) envelope on its surface, characterized in that the above-mentioned expression vector pBR-peg-PRRSV-QT7 is introduced into the pan-inert carrier Salmonella S9H by electroporation, and the expression of the Peg pili of Salmonella pullorum on the surface of S9H-pBR-peg-PRRSV-QT7 and the functional display of the conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the PRRSV-2 virus envelope on the surface of the S9H-pBR-peg-PRRSV-QT7 recombinant bacterium are verified by a plate agglutination test.
[0029] The present invention also provides the use of the neutralizing epitope QT7, the nucleic acid molecule, the peg-PRRSV-QT7 gene fragment, the expression cassette, the recombinant expression vector, the recombinant cell or the recombinant strain in the preparation of a reagent or a kit for detecting PRRSV-2 antibodies or vaccines thereof.
[0030] Wherein, the antibody is a neutralizing antibody.
[0031] The present invention also provides an in vitro plate agglutination test detection method directly mediated by a neutralizing antibody and a conserved neutralizing epitope antigen QT7. The detection antigen in the plate agglutination test detection method is a S9H-pBR-peg-PRRSV-QT7 recombinant bacterium that displays the conserved neutralizing epitope QT7 of the PRRSV-2GP5 protein on its surface. The detection control is S9H-pBR-peg. Compared with the detection antigen, the detection control only lacks the conserved neutralizing epitope QT7, thereby ensuring the specificity of the detection.
[0032] The present invention also provides a neutralizing antibody of the conserved neutralizing epitope antigen QT7, wherein the neutralizing antibody is obtained by immunizing an animal with the recombinant strain or the recombinant protein expressing the conserved neutralizing epitope QT7.
[0033] The present invention also provides a detection system or a detection kit for North American porcine reproductive and respiratory syndrome virus antibodies, wherein the detection system or the detection kit for North American porcine reproductive and respiratory syndrome virus antibodies comprises the expression cassette, the recombinant expression vector, the recombinant cell or the recombinant strain.
[0034] The agglutination antibody level measured by the neutralizing antibody direct-mediated plate agglutination test detection method for the conserved neutralizing epitope antigen QT7 provided by the present invention is strongly positively correlated with the PRRSV-2 neutralizing antibody level measured by the classic cell neutralization test (tested in MARC-145 passage cells and PAM primary cells cultured in vitro using PRRSV-2 adapted strains).
[0035] The convenient detection method of the conserved neutralizing epitope antigen QT7-neutralizing antibody directly mediated plate agglutination test established by the present invention has potential application prospects in the immune effect of PRRSV-2 vaccine, and the evaluation and prevention and control of anti-PRRSV-2 neutralizing antibodies.
[0036] Beneficial effects: Compared with the prior art, the present invention has the following significant advantages: First, the neutralizing epitope of the major glycoprotein GP5 of the envelope of North American porcine reproductive and respiratory syndrome virus (PRRSV-2) provided by the present invention is the main epitope of the PRRSV-2 virus stimulating the body to produce neutralizing antibodies, which can specifically recognize the corresponding neutralizing antibodies and produce a specific neutralizing immune response in vivo. Similarly, the anti-PRRSV-2 neutralizing antibodies produced in pigs can recognize the neutralizing epitope of GP5 and produce a specific neutralizing immune response; secondly, the present invention Compared with the detection control S9H-pBR-peg, the detection antigen S9H-pBR-peg-PRRSV-QT7 only adds the conservative neutralizing epitope QT7, which ensures the specificity of the plate agglutination test detection method directly mediated by the conservative neutralizing epitope antigen QT7-neutralizing antibody; at the same time, the Peg pili display expression system can be used to amplify the conservative neutralizing epitope QT7 of the main glycoprotein GP5 of the PRRSV-2 virus envelope on the surface of the inert carrier bacteria S9H. In theory, 5 μL of the detection reagent can contain 10 13 The neutralizing epitope QT7 ensures the sensitivity of the detection; at the same time, the neutralizing epitope QT7 selected by the present invention is a conserved epitope of the reported PRRSV-2 strains, and the established conserved neutralizing epitope antigen QT7-neutralizing antibody directly mediated in vitro plate agglutination test detection method does not require the cultivation of cells and viruses, thereby overcoming the limitation of needing to select different strains and different types of susceptible cells; the plate agglutination test can be observed with the naked eye within two minutes to determine the result by whether agglutinated particles appear, and does not require specially trained laboratory personnel and sophisticated laboratory instruments. The low detection cost and convenience can be used for large-scale rapid detection in large-scale pig farms; at the same time, the method has good repeatability. The present invention establishes a conserved neutralizing epitope QT7--neutralizing antibody-directed plate agglutination test, and the agglutination antibody level determined by the agglutination test is strongly positively correlated with the PRRSV-2 neutralizing antibody level tested by the classic cell neutralization test (tested in MARC-145 passage cells and PAM primary cells cultured in vitro using PRRSV-2 adapted strains) (p<0.0001, r=0.634). In summary, the present invention provides a convenient detection method for agglutination test that is fast, convenient, low-cost, specifically sensitive, not affected by different strains and different cells, and has stable results and good repeatability. This method has potential application prospects in the immune effect of PRRSV-2 vaccines, and the evaluation and prevention and control of anti-PRRSV-2 neutralizing antibodies. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 , Schematic diagram of the recombinant expression vector pBR-peg-PRRSV-QT7 plasmid.
[0038] Figure 2 Electrophoretogram of PCR amplification and identification of peg operon of peg-PRRSV-QT7 and Salmonella pullorum standard strain CVCC 526, where lane M is Trans 2K plus II DNA Marker, lane 1 is the genome amplification product of DH5α engineered bacteria as a negative control, lane 2 is the amplification product of pUC57-peg-PRRSV-QT7, and lane 3 is the PCR amplification product of Salmonella pullorum standard strain CVCC 526.
[0039] Figure 3 , nucleic acid electrophoresis diagram of expression vector pBR-peg-PRRSV-QT7 and pBR-peg digestion identification. Lane M is Trans 2K plus II DNA Marker, lane 1 is pBR322 circular plasmid, lane 2 is recombinant circular plasmid pBR-peg-PRRSV-QT7, lane 3 is the product of double digestion of pBR-peg-PRRSV-QT7 by Nhe I and Eag I, lane 4 is the recombinant circular plasmid pBR-peg, and lane 5 is the product of double digestion of pBR-peg by Nhe I and Eag I.
[0040] Figure 4 , schematic diagram of the positive and negative detection method of the in vitro plate agglutination test mediated directly by the conserved neutralizing epitope antigen QT7 - neutralizing antibodies, in which the detection antigen S9H-pBR-peg-PRRSV-QT7 and the detection control S9H-pBR-peg do not react with the negative serum, there are no agglutinated particles in the reaction solution, and the background is turbid; the detection control S9H-pBR-peg does not react with the PRRSV-2 positive serum (no agglutinated particles, the background is turbid), while the detection antigen S9H-pBR-peg-PRRSV-QT7 and the PRRSV-2 positive serum produce visible agglutinated particles (white agglutinated particles are deposited on both sides of the reaction solution), "-" represents a negative agglutination reaction, and "+" represents a positive agglutination reaction. The agglutinated particles are marked with red arrows in the figure.
[0041] Figure 5 , and the acquisition of neutralizing antibodies against the conserved neutralizing epitope antigen QT7. The PRRSV-2 neutralizing antibodies and antibody titers in the serum were measured using a classic cell neutralization assay, and no PRRSV-2 neutralizing antibodies were detected in the control group. DETAILED DESCRIPTION
[0042] The embodiments of the present invention will be further described below in conjunction with examples. Obviously, the examples are intended to illustrate the present invention and should not be regarded as limiting the scope of the present invention. In addition to the specific methods, equipment, and materials used in the examples, according to the prior art mastery of those skilled in the art and the records of the present invention, any methods, equipment, and materials of the prior art similar to or equivalent to the methods, equipment, and materials described in the examples of the present invention can also be used to implement the present invention.
[0043] Example 1. Comparison and analysis of the protein sequence of the major glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus (PRRSV-2) envelope and acquisition of the sequence of the conserved neutralizing epitope QT7
[0044] The sequence of PRRSV-2GP5 protein uploaded by the National Center for Biotechnology Information (NCBI) was used for sequence alignment and analysis. The conserved sequence of GP5 protein was selected for further analysis, and the neutralizing epitope of GP5 protein was determined according to the prediction results of the B cell epitope online prediction website (www.iedb.org). The conserved amino acid sequence of PRRSV-2GP5 neutralizing epitope was optimized and selected and named QT7: QLIYNLT.
[0045] The nucleotide sequence of the conserved neutralizing epitope QT7 of the GP5 protein of North American porcine reproductive and respiratory syndrome virus (PRRSV-2) (SEQ ID NO.1): CAGCTGATTTACAACTTGACG.
[0046] Example 2 Selection of substitution sites for the conserved neutralizing epitope QT7 of PRRSV-2 GP5 in Peg pili
[0047] According to the Salmonella Pullorum CVCC 526peg operon sequence in SEQ ID NO.4, the PredictProtein online website (https: / / predictprotein.org / ) was used to predict the major subunit PegA of Salmonella pullorum CVCC526Peg pili (its position in the peg operon is 1-534bp), and the amino acids exposed on the surface of PegA were found. At the same time, the protein tertiary structure online prediction website SWISS-MODEL was used to predict the spatial structure of PegA. The protein analysis software Pymol (https: / / pymol.org / 2 / ) was used to visualize the spatial structure of PegA, verify and further analyze the amino acids exposed on the surface of PegA, and the better exposed position in the PegA protein was selected as the replacement site of the conserved neutralizing epitope QT7 of PRRSV-2GP5. Its position in PegA is 63-69aa from the N-terminus of the PegA protein and 187-207bp in the pegA gene.
[0048] Example 3 Construction of expression vectors pBR-peg-PRRSV-QT7 and pBR-peg
[0049] According to the Salmonella Pullorum CVCC 526 peg operon sequence in SEQ ID NO.4, the above-determined PRRSV-2GP5 conserved neutralizing epitope QT7 sequence and the alternative site of PRRSV-2GP5 neutralizing epitope QT7 in pegA, a plasmid containing the full-length peg operon nucleotide sequence of the PRRSV-2GP5 conserved neutralizing epitope QT7 was synthesized by Beijing Qingke Biotechnology Co., Ltd. and named pUC57-peg-PRRSV-QT7. At the same time, a pair of molecular cloning primers were designed for peg-PRRSV-QT7 (SEQ ID NO.2), and the upstream primer was peg-F: 5′-CTA GCTAGC ATGAAACGTTCACTTATTGCTGCT-3′; downstream primer is peg-R: 5′-GAT CGGCCGTTAATCA GTTAATACCGTCATCGTCAG-3′, the underlined sequences represent the restriction sites of Nhe I and Eag I, respectively. pUC57-peg-PRRSV-QT7 was used as a template, and the upstream and downstream primers peg-F / R were used to amplify the full length of peg-PRRSV-QT7. The amplification system was 1 μL of pfu high-fidelity DNA Polymerase (Beijing Quanshijin Biotechnology Co., Ltd.), 10 μL of 5×pfu DNA polymerase buffer, 4 μL of dNTPs, 1 μL of each upstream and downstream primer (10 μM), 1 μL of pUC57-peg-PRRSV-QT7 template, and 32 μL of ultrapure water. After the above system was mixed evenly, PCR amplification was performed using a thermal cycler (Bio-Red). The PCR program was: 95°C pre-denaturation for 5 min; 94°C denaturation for 30 s, 60°C annealing for 30 s, 72°C extension for 3 min, 30 cycles; 72°C extension for another 10 min; after the amplification, the temperature was lowered to 12°C for storage. The genome of Salmonella pullorum CVCC 526 was used as a positive control; the genome of Escherichia coli engineered bacteria DH5α was used as a negative control.
[0050] The PCR products were electrophoresed in 1.0% agarose gel at 110V. After the electrophoresis, the products were stained with ethidium bromide and the results were observed using a gel imager. Figure 2 As shown, both Salmonella pullorum CVCC 526 and pUC57-peg-PRRSV-QT7 amplified a DNA product of 4850 bp, while the genome of the Escherichia coli engineered bacteria DH5α did not amplify any band. The peg-PRRSV-QT7 amplified by pUC57-peg-PRRSV-QT7 and the full-length peg operon (SEQ ID NO. 4) amplified by PCR from the genome of Salmonella pullorum CVCC 526 were purified using a universal DNA purification and recovery kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., Cat. No.: DP214) and stored at -20°C for future use.
[0051] E. coli DH5α engineered bacteria were preserved in this laboratory and stored in -80℃ cryotubes. DH5α was streaked on LB plates and incubated inverted overnight at 37℃. A single colony was picked and placed in 4mL fresh LB medium. The culture was shaken and incubated at 37℃ and 220rpm overnight. After one generation of transfer, the bacterial solution was transferred to 40mL fresh LB medium at a ratio of 1:100 and the OD was 0. 600=0.4-0.6, ice-bath the bacterial solution for 30 minutes, centrifuge at 4°C, 4000rpm for 10 minutes, then resuspend with 10% glycerol pre-cooled in ice, centrifuge at 4°C, 4000rpm for 10 minutes, repeat the 10% glycerol washing for 3 times, and finally resuspend with 40μL of 10% glycerol per 4mL bacterial solution, and dispense 100μL / cell to prepare DH5α electroporation competent state. The pBR322 plasmid purchased from the Miaoling plasmid platform was electroporated into the DH5α competent state at a voltage of 1.8KV using an electroporator to obtain the DH5α recombinant bacteria containing the pBR322 plasmid, and stored at -80°C. The DH5α containing the pBR322 plasmid stored in a -80°C cryopreservation tube was streaked on a tube containing ampicillin (Amp + ) on LB plates, incubate at 37°C overnight, pick a single colony and add it to 4 mL of fresh Amp + The liquid LB medium was cultured at 37°C with shaking at 220 rpm overnight, and the next day, the medium was transferred at a ratio of 1:100 to 4 mL of fresh LB medium containing Amp + Liquid LB medium, 37 ° C, 220rpm overnight shaking culture, use the rapid plasmid extraction kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., catalog number: DP105) to extract the pBR322 plasmid. Use Nhe I and Eag I restriction endonucleases (NEB, Beijing) to double-digest the extracted pBR322 plasmid and the purified peg-PRRSV-QT7 fragment and the full-length peg operon, prepare a 1.0% agarose gel, perform electrophoresis at 110V, cut the target band and purify it using a universal DNA purification and recovery kit, and then use T4 DNA ligase (NEB, Beijing) to connect the purified pBR322 plasmid digestion fragment with the peg-PRRSV-QT7 digestion fragment and the peg operon digestion fragment in a 16 ° C metal bath overnight. The next day, the ligation product was transformed into DH5α competent cells and coated with 100μg / mL Amp + After inverted culture at 37℃ for 16h, single colonies were picked and inoculated into a plate containing 100μg / mL Amp + LB liquid medium, overnight culture, extract plasmid, double digest with Nhe I and Eag I endonucleases. Prepare 1% agarose gel, electrophoresis at 110V for 45min, stain with ethidium bromide, and image under UV imaging. The results are as follows Figure 3As shown, the double enzyme digestion products of the recombinant plasmid pBR-peg-PRRSV-QT7 were 3655 bp of linear pBR322 vector and 4850 bp of peg-PRRSV-QT7 linear DNA fragment; the double enzyme digestion products of the recombinant plasmid pBR-peg were 3655 bp of linear pBR322 vector and 4850 bp of peg linear DNA fragment (SEQ ID NO.4), which were consistent with expectations. The recombinant plasmids were named pBR-peg-PRRSV-QT7 and pBR-peg, respectively. A pair of identification primers were designed for pegA to identify whether PRRSV-QT7 was inserted into the expected position in pegA. The upstream primer was pegA-F: 5′-ATGAAACGTTCACTTATTGCTGCT-3′; the downstream primer was pegA-R: 5′-TTAATCAGTTAATACCGTCATCGTCA-3′. The pBR-peg-PRRSV-QT7 plasmid and the identification primers were sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing, and it was verified and found that PRRSV-QT7 was inserted into the expected position in pegA.
[0052] Example 4 Construction and functional verification of the in vitro plate agglutination test method for the conserved neutralizing epitope antigen QT7-neutralizing antibody direct mediator
[0053] The S9H (inert carrier Salmonella S9H has obtained a national invention patent; Zhu Guoqiang, Yang Bin, Yang Yang, Meng Xia, Xia Pengpeng, Duan Qiangde, Zhu Xiaofang. A pan-type inert carrier Salmonella and its potential application, ZL202010427735.8) stored in a -80℃ cryotube was streaked onto solid LB medium, incubated at 37℃ for 24h, and then a single colony was picked up and transferred to 4mL fresh LB liquid medium. The culture was shaken at 37℃ and 220rpm for 12h. After the first generation, the bacterial solution was transferred to a 50mL centrifuge tube containing 40mL LB medium at a ratio of 1:100, and shaken at 37℃ until the OD 600 =0.4-0.6, place the 50mL centrifuge tube in an ice bath for 30min, centrifuge at 4°C, 4000rpm for 10min, then resuspend with 10% glycerol pre-cooled in ice, centrifuge at 4°C, 4000rpm for 10min, repeat the washing of the bacteria with 10% glycerol for 3 times, finally resuspend with 40μL of 10% glycerol for every 4mL of bacterial solution, aliquot at 100μL / tube to make S9H competent state, and freeze at -80°C for later use.
[0054] 200 ng of pBR-peg-PRRSV-QT7 plasmid and pBR-peg plasmid were mixed with 100 μL S9H competent medium, electroporated at 2.2 KV using an electroporator, and then 1 mL SOC medium was added and cultured at 37 °C with shaking for 1 h. 200 μL of bacterial solution was spread on a plate containing 100 μg / mL Amp + LB plates were plated and inverted at 37°C. Positive clones were picked and identified using pegA-F / R. The positive clones containing pBR-peg-PRRSV-QT7 were named S9H-pBR-peg-PRRSV-QT7, and the positive clones containing pBR-peg were named S9H-pBR-peg.
[0055] S9H-pBR-peg-PRRSV-QT7 and S9H-pBR-peg were mixed in the presence of 100 μg / mL Amp + The cells were grown in LB liquid medium to the stationary phase, centrifuged at 4000 rpm for 5 min, and the supernatant was discarded. The cells were resuspended with an equal volume of sterile saline and washed twice to prepare S9H-pBR-peg-PRRSV-QT7 and S9H-pBR-peg bacterial suspensions (final concentration 1×10 10 CFU / mL).
[0056] Agglutination test was performed with S9H-pBR-peg-PRRSV-QT7 bacterial suspension and S9H-pBR-peg bacterial suspension and negative chicken serum (90-day-old SPF chicken serum) and Salmonella pullorum positive serum (90-day-old SPF chickens were immunized twice with Salmonella pullorum standard strain CVCC 526, and blood was collected 45 days after immunization) and S9H (S9H-pBR322) bacterial suspension containing pBR322 empty vector was used as negative control. The results are shown in Table 1, and the bacterial suspensions of S9H-pBR-peg-PRRSV-QT7, S9H-pBR-peg and S9H-pBR322 did not react with negative serum. Both S9H-pBR-peg-PRRSV-QT7 bacterial suspension and S9H-pBR-peg bacterial suspension showed significant agglutination with positive serum of Salmonella pullorum, and white agglutinated particles were deposited on both sides of the reaction solution; while S9H-pBR322 bacterial suspension containing pBR322 empty vector did not agglutinate with positive serum, there were no agglutinated particles, and the background was turbid. This result shows that the positive serum of Salmonella pullorum is specifically recognized by the Peg pili of Salmonella pullorum, and the Peg pili of Salmonella pullorum can be successfully functionally expressed on the surface of the pan-inert carrier Salmonella S9H.
[0057] Table 1 Verification of the functional display of Salmonella pullorum Peg pili on the surface of the pan-inert carrier Salmonella S9H
[0058]
[0059] The above-mentioned S9H-pBR-peg-PRRSV-QT7 bacterial suspension was mixed with 3 negative sera of SPF pigs (kindly donated by Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences), 10 sera of non-immunized piglets (collected in our laboratory from newborn piglets provided by Huaweite (Jiangsu) Biopharmaceutical Co., Ltd.) and positive sera of various PRRSV subtypes (10 sera immune with the live attenuated vaccine strain TJM-F92 of the highly pathogenic PRRSV strain TJM, sampled 42 days after the first vaccination and 21 days after the second vaccination, and obtained by Huaweite (Jiangsu) Biopharmaceutical Co., Ltd.) Co., Ltd.; 10 sera from pigs immunized with the inactivated vaccine of the classical strain CH-1a, which were collected 58 days after the first vaccination and 27 days after the second vaccination, were donated by Zhejiang Meibaolong Biotechnology Co., Ltd.; 2 sera from pigs challenged with the NADC30-like strain CHsx1401 were donated by China Agricultural University, and 5 sera from pigs challenged with the NADC34-like strain were donated by Yangzhou Youbang Biopharmaceutical Co., Ltd.) were used for agglutination tests, and the S9H-pBR-peg bacterial suspension containing pBR-peg was used as a negative control. The results are shown in Table 2. Neither S9H-pBR-peg-PRRSV-QT7 bacterial suspension nor S9H-pBR-peg bacterial suspension agglutinated with negative serum of SPF pigs or serum of non-immunized piglets. S9H-pBR-peg-PRRSV-QT7 bacterial suspension and positive serum of various PRRSV subtype strains showed significant agglutination, and white agglutinated particles were deposited on both sides of the reaction solution. However, neither the S9H-pBR-peg control nor the positive serum showed agglutination, no agglutinated particles, and the background was turbid. This result shows that the conserved neutralizing epitope QT7 of PRRSV-2GP5 protein can be expressed on the surface of pan-type inert carrier Salmonella through Peg pili, and can detect antibodies against PRRSV-2. S9H-pBR-peg is used as a detection control in this detection method. Compared with the detection antigen S9H-pBR-peg-PRRSV-QT7, the detection control only lacks the conserved neutralizing epitope QT7, ensuring the specificity of the detection results.
[0060] Table 2 Functional verification of the expression of the conserved neutralizing epitope QT7 of PRRSV-2GP5 on the surface of S9H
[0061]
[0062] Note: “-” represents negative agglutination reaction; “+” represents positive agglutination reaction
[0063] Example 5 Specificity and sensitivity test of the in vitro plate agglutination test method for the conserved neutralizing epitope antigen QT7-neutralizing antibody direct mediator
[0064] According to the method in Example 4, a detection control S9H-pBR-peg bacterial suspension and a detection antigen S9H-pBR-peg-PRRSV-QT7 bacterial suspension were prepared, and the above two bacterial suspensions were subjected to agglutination tests with positive sera / antibodies of different pathogens to verify the specificity of the plate agglutination detection method. The sera / antibodies used included: 20 unimmunized piglet sera (collected in this laboratory from Weite (Jiangsu) Biopharmaceutical Co., Ltd. to provide weaned piglets), 49 PRRSV TJM-F92 live attenuated vaccine immune sera (donated by Weite (Jiangsu) Biopharmaceutical Co., Ltd.), 15 Escherichia coli C83902 positive sera (10 donated by Yangzhou Youbang Biopharmaceutical Co., Ltd., and 5 sera were stored in this laboratory), 15 ASFV positive sera (donated by the Military Veterinary Research Institute of the Academy of Military Medical Sciences (Changchun), 20 CSFV positive sera (donated by the Military Veterinary Research Institute of the Academy of Military Medical Sciences (Changchun), and 5 PCV2 Cap rabbit polyclonal antibodies (donated by Yangzhou Youbang Biopharmaceutical Co., Ltd.). The test results are shown in Table 3. The S9H-pBR-peg test control did not agglutinate with all sera / antibodies; S9H-pBR-peg-PRRSV-QT7 only reacted with PRRSV positive sera (49 PRRSV TJM-F92 live attenuated vaccine immune sera), but did not react with negative sera (20 non-immunized piglet sera) and other sera / antibodies (15 ETEC C83902 positive sera, 15 ASFV positive sera, 20 CSFV positive sera, and 5 PCV2 Cap rabbit polyclonal antibodies).
[0065] Table 3 Specificity validation of the in vitro plate agglutination test method for the conserved neutralizing epitope antigen QT7-neutralizing antibody direct mediator
[0066]
[0067] Note: “-” represents negative agglutination reaction; “+” represents positive agglutination reaction
[0068] To test the sensitivity of the method, 8 weaned piglets with negative PRRSV antigen and antibody were screened, of which 4 piglets were raised in a separate room as a control group, and the other 4 piglets were immunized with the PRRSV attenuated strain CH-1a (GenBank accession number: AY032626.1). After immunization, whole blood of all pigs was collected continuously, and after serum was separated, the in vitro plate agglutination test directly mediated by the neutralizing antibody of the conserved neutralizing epitope antigen QT7 of the present invention was used to detect the PRRSV-2 agglutination antibody titer in the serum. Specifically: 30 μL of sterile saline was added to each well of the well plate, and then 30 μL of serum was taken and fully mixed with the saline in the well, and 30 μL was drawn into the next well to which 30 μL of saline had been added, so that the serum was serially diluted, and the serum of each dilution was subjected to a plate agglutination test with S9H-pBR-peg control and S9H-pBR-peg-PRRSV-QT7. According to the requirements of the positive reaction quantitative test, the highest dilution with agglutinated particles was the PRRSV-2 agglutination antibody titer in the serum. The antibody titer test results of the immunized pig serum are shown in Table 4. The in vitro plate agglutination test method directly mediated by the conservative neutralizing epitope antigen QT7-neutralizing antibody of the present invention can detect PRRSV-2 agglutination antibodies in the immunized pig serum as early as the 5th day, with high sensitivity, significantly earlier than the time when the neutralizing antibody is measured in the cell neutralization test (PRRSV-2 neutralizing antibody is detected as early as the 36th day after immunization).
[0069] Table 4 Sensitivity validation of the in vitro plate agglutination test method for the conserved neutralizing epitope antigen QT7-neutralizing antibody direct mediator
[0070]
[0071]
[0072]
[0073] Note: All control pigs were negative; "-" represents negative agglutination reaction; "+, 1:1" represents positive agglutination reaction / neutralizing antibody, and the titer is 1:1
[0074] Example 6 Conserved neutralizing epitope antigen QT7 - Comparison of the results of the in vitro plate agglutination test mediated directly by neutralizing antibodies and the results of the cell neutralization test
[0075] PRRSV-2GP5 protein is the main protein that PRRSV stimulates the body to produce neutralizing antibodies. In order to explore the correlation between the agglutination antibody level measured by the conserved neutralizing antigen epitope QT7 of the GP5 protein provided by the present invention and the PRRSV-2 neutralizing antibody level measured in the cell neutralization test, sera from different sources were tested simultaneously using two methods. The tested sera included: 25 sera provided by third-party unit 1 (including 2 negative sera and 23 PRRSV-2 neutralizing antibody positive sera); 4 immune sera provided by third-party unit 2 (all with a certain PRRSV-2 neutralizing antibody titer), and 25 sera provided by third-party unit 3 (all with a certain PRRSV-2 neutralizing antibody titer).
[0076] The serum provided by the third party unit 1 was tested using the present invention and the traditional cell neutralization test, and the test results were compared as shown in Table 5. For 2 PRRSV-negative sera, the test results of the two detection methods were all negative, and the two were consistent; and the anti-PRRSV-2 neutralizing antibodies determined by the 23 cell neutralization tests were all determined to be positive sera, and the plate agglutination detection method of the present invention also detected positive, and the two were also completely consistent. Through quantitative detection and data results, it was found that there was a certain correlation between the antibody titers detected by the two methods. It is worth noting that since the cell neutralization test is time-consuming, labor-intensive, and consumable, the test results of the cell neutralization test are rarely repeated and reviewed by different testers at different times. Considering that the repeatability of the cell neutralization test is affected by many factors, the same serum is tested at different times by different testers, and the test results often have certain titer differences, but the method of the present invention is easy to repeat, and consistent results can be obtained each time after three repetitions.
[0077] Table 5. Comparison of the results of the in vitro plate agglutination test method and the cell neutralization test method for the conserved neutralizing epitope antigen QT7
[0078]
[0079]
[0080] The comparison of the test results of the two methods for the serum provided by the third party unit 2 is shown in Table 6. The four PRRSV-2 neutralizing antibody positive sera measured by the cell neutralization test can detect the agglutination antibody titer using the method of the present invention. It is worth noting that the third party unit 2 used different susceptible cells (MARC-145 cells and PAM cells) to perform a cell neutralization test on the same serum, and the measured PRRSV-2 neutralizing antibody titers were different.
[0081] Table 6. Comparison of the results of the in vitro plate agglutination test method and the cell neutralization test method for the conserved neutralizing epitope antigen QT7
[0082]
[0083] The comparison of the test results of the two methods for the serum provided by the third party unit 3 is shown in Table 7. The 25 PRRSV-2 neutralizing antibody positive sera measured by the cell neutralization test can detect the agglutination antibody titer using the method of the present invention, and the antibody titers detected by the two methods have a certain correlation. It is worth noting that the third party unit 3 used different PRRSV-2 strains to conduct a cell neutralization test on the same serum, and the measured PRRSV-2 neutralizing antibody titers were different.
[0084] Table 7. Comparison of the results of the in vitro plate agglutination test and the cell neutralization test for the conserved neutralizing epitope antigen QT7
[0085]
[0086]
[0087] Note: CH-1a is a transitional strain from classic PRRSV to HP-PRRSV, with low pathogenicity.
[0088] In order to further quantitatively analyze the correlation between the agglutination antibody level measured by the present invention and the PRRSV-2 neutralizing antibody level measured by the cell neutralization test, the antibody levels measured by the two methods were tested using the non-parametric Spearman rank test (IBM SPSS Statistics 26). At the same time, in order to improve the accuracy of the analysis and avoid the lack of statistical analysis power due to the small number of samples, so that the potential relationship cannot be analyzed, the agglutination antibody level and the PRRSV-2 neutralizing antibody level of 96 sera were analyzed in combination with the sera of the above-mentioned three third-party units and the clinical / laboratory PRRSV-2 vaccine immune sera, and it was found that the agglutination antibody level measured by the present invention was strongly positively correlated with the PRRSV-2 neutralizing antibody level measured by the cell neutralization test, and the correlation coefficient (r) was 0.634 (r>0.6 is a strong correlation), p<0.0001.
[0089] Example 7 Obtaining neutralizing antibodies against the conserved neutralizing epitope antigen QT7
[0090] Ten 30-day-old PRRSV antigen-antibody negative weaned piglets (provided by Huaweit (Jiangsu) Biopharmaceutical Co., Ltd.), of which five were used as the immune group and intramuscularly immunized with S9H-pBR-peg-PRRSV-QT7, with an immunization bacterial dose of 5×10 9CFU / head, and the other 5 piglets were kept separately in another room as the control group and injected with the same volume and amount of S9H-pBR-peg; 14 days after the first vaccination, the 5 piglets in the immunized group were given a booster vaccination according to the same procedure, and blood was collected and serum was separated every week after immunization, and the level of PRRSV-2 neutralizing antibodies in the serum was determined using a classic cell neutralization test. Figure 5 As shown, after piglets were immunized with S9H-pBR-peg-PRRSV-QT7, PRRSV-2 neutralizing antibodies were produced on the 7th day. On the 14th day after immunization, the PRRSV-2 neutralizing antibody titer of piglets immunized with S9H-pBR-peg-PRRSV-QT7 could reach 1:16. No PRRSV-2 neutralizing antibodies were detected in piglets in the S9H-pBR-peg control group that did not express the conserved neutralizing antigen epitope QT7 of GP5 protein.
[0091] In summary, the present invention provides a conserved neutralizing epitope QLIYNLT (QT7) on the surface of the major glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus (PRRSV-2) envelope and a conserved neutralizing epitope antigen QT7-neutralizing antibody directly mediated in vitro plate agglutination test detection method, and the agglutination antibody level measured by this method is strongly positively correlated with the PRRSV-2 neutralizing antibody level measured in a cell neutralization test. This method has potential application prospects in the immune effect of PRRSV vaccine, anti-PRRSV-2 neutralizing antibody evaluation and prevention and control. The in vitro plate agglutination test directly mediated by the neutralizing antibody and the conserved neutralizing epitope antigen QT7 of the present invention is used to detect the level of PRRSV-2 neutralizing antibodies in samples (serum), which has good specificity, sensitivity and repeatability; it overcomes the need for susceptible cells and strains, has the advantages of being fast and convenient, and can be used for large-scale rapid detection in large-scale pig farms due to its low detection cost and convenience; in addition, unlike the lack of unified standards in cell neutralization tests between different units, which makes it impossible to compare the results, the PRRSV-2 neutralizing antibody results measured using this method are consistent, stable and repeatable.
Claims
1. A conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the North American porcine reproductive and respiratory syndrome virus envelope, characterized in that: The amino acid sequence of the conserved neutralizing epitope QT7 is QLIYNLT.
2. A nucleic acid molecule encoding the conserved neutralization epitope QT7 according to claim 1, characterized in that: The nucleotide sequence of the nucleic acid molecule is shown in SEQ ID NO.
1.
3. A peg-PRRSV-QT7 A gene fragment, characterized in that The nucleotide sequence is shown in SEQ ID NO.
2.
4. A recombinant protein expressing a conserved neutralizing epitope QT7, characterized in that: The amino acid sequence of the recombinant protein is shown in SEQ ID NO.
3.
5. An expression cassette, a recombinant expression vector, a recombinant cell or a recombinant strain, characterized in that: It comprises the nucleic acid molecule according to claim 2 or the nucleic acid molecule according to claim 3 peg-PRRSV-QT7 Gene fragment.
6. The method for constructing the recombinant expression vector according to claim 5, characterized in that: The following steps are involved: (1) obtaining the gene sequence of the conserved neutralizing epitope QT7 of the major glycoprotein GP5 of the envelope of the North American porcine reproductive and respiratory syndrome virus, as shown in the nucleotide sequence of SEQ ID NO.1; (2) Inserting the gene sequence obtained in step (1) into the Peg pili encoding gene sequence to construct a recombinant expression vector.
7. The method for constructing the recombinant strain according to claim 5, characterized in that: The method comprises the following steps: introducing the recombinant expression vector into the carrier bacteria by means of electrotransformation.
8. The neutralizing epitope QT7 according to claim 1, the nucleic acid molecule according to claim 2, and the peg- PRRSV-QT7 Use of the gene fragment, the recombinant protein according to claim 4, the expression cassette, the recombinant expression vector, the recombinant cell or the recombinant strain according to claim 5 in the preparation of a reagent or a kit for detecting PRRSV-2 antibodies.
9. A detection system or a detection kit for North American porcine reproductive and respiratory syndrome virus or its antibody, characterized in that: The detection system or detection kit for North American porcine reproductive and respiratory syndrome virus or its antibody comprises the expression cassette, recombinant expression vector, recombinant cell or recombinant strain according to claim 5.
Citation Information
Cited By
Monoclonal antibody for resisting porcine CD163 molecule FP14 epitope peptide, hybridoma cell strain 1F9E2 and application
CN120944831A
Porcine reproductive and respiratory syndrome virus receptor CD163 key SRCR5 structural domain epitope peptide, epitope peptide vaccine and application
CN120965854A
Porcine reproductive and respiratory syndrome virus receptor cd163 key srcr5 domain epitope peptide and epitope peptide vaccine and application
CN120965854B
Gv07 epitope peptide, hybridoma cell strain and monoclonal antibody of antigen epitope gv07 and application
CN122958549A
